


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:


Claims 1-32 (cancelled).

Claim 33 (previously presented): A compound having the general formula (I):



wherein:

- (i) R₁ represents an unsubstituted C₆ or C₁₀ aryl group; or a C₆ aryl group substituted with Me or OMe;
- (ii) A represents O, S or a sulfur atom oxidized to a sulfoxide;
- (iii) the cyclic group labeled F represents an unsubstituted C₆ or C₁₀ aryl or a C₅ heteroaryl group having nitrogen as a heteroatom or a phenyl group substituted with ethoxycarbonyl function; and
- (iv) Y represents the group



wherein R₂ and R₃ are independently hydrogen; or methyl or ethyl;
or Y represents the group CH₃, or (CH₂)₂CH₃ or an unsubstituted C₅ heteroaryl group having nitrogen as a heteroatom.

Claim 34 (previously presented): The compound of claim 33 wherein R₁ is an unsubstituted 1-naphthyl group.

Claim 35 (previously presented): The compound of claim 33 wherein F is an unsubstituted phenyl group or an unsubstituted naphthyl or 2,3-pyridine.

Claim 36 (previously presented): The compound of claim 33 wherein R₁ and F represent a 1-naphthyl group and a 2,3-naphto-fused group, respectively.

Claim 37 (previously presented): The compound of claim 33 wherein Y is selected from the group consisting of CH₃ or N(Me)₂, NHMe or a 4-pyridine group.


Claim 38 (previously presented): A compound of claim 33 selected from the group consisting of:

4-Acetoxy-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,
4-[(Dimethylcarbamoyl)oxy]-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,
7-[(Methylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]-benzoxazepine,
7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,
7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,
7-Acetoxy-6-(1-naphthyl)pyrrolo[1,2-d]pyrido[3,2-b][1,4]oxazepine,
4-Acetoxy-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
4-[(Dimethylcarbamoyl)oxy]-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4]oxazepine, 7-[(Ethylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,
7-[(Methylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,
7-Isonicotinoyloxy-6-(p-methoxyphenyl)pyrrolo[2,1-d][1,5]benzothiazepine, or
7-(Butyryloxy)-6-(p-methoxyphenyl)pyrrolo[2,1-d][1,5]benzothiazepine 5-oxide.

Claim 39 (previously amended): A pharmaceutical composition comprising the compound of any one of claims 33-38 and a pharmaceutically acceptable carrier.


Claim 40-44 (cancelled).

Claim 45 (currently amended): A method for selective apoptosis in cancerous cell lines conditions selected from the group consisting of leukemic T-cell lymphoblast cells (Jurkat), promyelocytic leukemia cells (HL-60), T-cell leukemia cells (Hut-78), chronic myeloid lymphoma cells (CML), T lymphoblastoid cells (CEM), cervix carcinoma cells (HeLa) and human breast carcinoma cells (MCF-7) leukemia, lymphoma, cervical cancer and breast cancer, comprising:
administering to a subject in need thereof, a pharmaceutically effective amount of a compound of formula I



wherein:

- (i) R₁ represents an unsubstituted C₆ or C₁₀ aryl group; or a C₆ aryl group substituted with Me or OMe;
- (ii) A represents O, S; or a sulfur atom oxidized to sulfoxide;
- (iii) the cyclic group labeled F represents an unsubstituted C₆ or C₁₀ aryl or a C₅ heteroaryl group having nitrogen as a heteroatom or a phenyl group substituted with ethoxycarbonyl function; and
- (iv) Y represents the group



wherein R₂ and R₃ are independently hydrogen; or methyl or ethyl;
or Y represents the group CH₃; or (CH₂)₂CH₃ or an unsubstituted C₅ heteroaryl group

having nitrogen as a heteroatom; and
assessing the affects of the administration.

Claim 46 (cancelled).

Claim 47 (previously presented): The method of claim 45 wherein the subject is a human or animal.

Claim 48 (currently amended): A method of claim 45 wherein the subject is administered a pharmaceutically effective amount of a compound is selected from the group consisting of:

4-Acetoxy-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,
4[(Dimethylcarbamoyl)oxy]-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,
7-[(Methylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]-benzoxazepine,
7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,
7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,
7-Acetoxy-6-(1-naphthyl)pyrrolo[1,2-d]pyrido[3,2-b][1,4]oxazepine,
4-Acetoxy-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
4-[(Dimethylcarbamoyl)oxy]-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4] oxazepine, 7-
[(Ethylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,
7-[(Methylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,
7-Isonicotinoyloxy-6-(p-methoxyphenyl)pyrrolo[2,1-d][1,5]benzothiazepine,
7-(Butyryloxy)-6-(p-methoxyphenyl)pyrrolo[2,1-d][1,5]benzothiazepine 5-Oxide.